Table 1

Patient characteristics and outcomes

Patient characteristics

Cohort M12

(N = 229)

Cohort M24

(N = 277)


Characteristics at ART start

Women (%)

151 (65.9)

173 (62.4)

Median age, years [IQR]

36.8 [32.0–42.3]

36.5 [30.8–42.6]

ARV naïve (%)*

225 (98.2)

273 (98.6)

Median follow-up before ART, months [IQR]

6.2 [3.9–11.4]

3.7 [1.8–7.7]

First ART regimen prescribed d4T/3TC/NVP

226 (98.7)

265 (95.7)

WHO stage 3 or 4 (%)

201 (87.7)

246 (88.8)

Body mass index <17 kg/m2 (%)

38 (17.8); n = 214

43 (16.8); n = 256

CD4 cell count, cells/mm3

n = 133

n = 239

Median [IQR]

100 [45–147]

93 [40–144]

<50 (%)

36 (27.1)

73 (30.5)


Characteristics at time of survey

Non-cumulative WHO stage at survey (%)

n = 223

n = 267

Asymptomatic

136 (61.0)

160 (59.9)

Stage 1 or 2

63 (28.2)

86 (32.2)

Stage 3 or 4

24 (10.8)

21 (7.9)

Body mass index, kg/m2

Median [IQR]

20.4 [18.9–22.0]

20.8 [19.0–22.5]

<18.5 kg/m2 (%)

43 (18.8)

52 (18.7)

Median weight gain since ART start, kg [IQR]

3 [1–6]

2 [0–7]


ARV-clinical related symptoms (%)

Asthenia

70 (30.7)

84 (30.3)

Digestive disorders

132 (57.6)

146 (52.7)

Neurological disorders

102 (44.5)

111 (40.1)

Dermatological disorders

70 (30.6)

84 (30.3)

Morphological disorders

39 (17.0)

72 (26.0)


CD4 cell count, cells/mm3

Median [IQR]

223 [163–308]

238 [172–321]

<200 (%)

92 (40.2)

100 (36.1)

Median gain since ART start [IQR]

+115 [59–170]

+139 [75–215]


Pills taken in last 4 days (%)

Good adherence

200 (87.3)

258 (93.1)

Poor adherence

29 (12.6)

19 (6.9)

30-day VAS (%)

Good adherence

198 (86.5)

250 (90.3)

Poor adherence

31 (13.5)

27 (9.7)


Plasmatic NVP level (%)

n = 204

n = 258

Low

39 (19.1)

32 (12.4)

Normal

115 (56.4)

172 (66.7)

High

50 (24.5)

54 (20.9)

Plasmatic EFV level (%)

n = 23

n = 18

Low

1 (4.4)

-

Normal

13 (56.5)

11 (61.1)

High

9 (39.1)

7 (38.9)


VAS, visual analogue scale; IQR, interquartile range

*ARV-naïve does not include women who received PMTCT prophylaxis.

Ahoua et al. BMC Infectious Diseases 2009 9:81   doi:10.1186/1471-2334-9-81

Open Data